Epigenetic Cancer Therapy, Second Edition provides a comprehensive discussion of healthy and aberrant epigenetic biology, along with new discoveries to improve our understanding of cancer epigenetics and therapeutics. The book encompasses large-scale intergovernmental initiatives, as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Since the publication of the first edition of this book, the field of epigenetics has undergone significant change. New epigenetic therapies have been designed and approved for clinical use.
Our knowledge of the plasticity of the epigenome in cancer and disease has expanded dramatically, with increasing evidence linking pollution to epigenetic changes in cancer development. This second edition has been fully updated to address these changes, along with promising therapeutic programs such as CRISPR/Cas9 mediated approaches, CAR-T based therapies, epigenetic priming, histone modifications, and similar, transformative advances across synthetic biology and cellular engineering.
1. Chapter 1 Introduction - p. 1 2. Chapter 2 Methylation and hydroxymethylation in cancer - p. 11 3. Chapter 3 Writers, erasers, and readers of DNA and histone methylation marks - p. 39 4. Chapter 4 Oncohistones - p. 65 5. Chapter 5 microRNA, epi-microRNA, and cancer - p. 85 6. Chapter 6 Long noncoding RNA in human cancers: to be or not to be, that is the question - p. 109 7. Chapter 7 The emerging roles of epitranscriptomic marks in cancer - p. 129 8. Chapter 8 Epigenomic profiling at genome scale: from assays and analysis to clinical insights - p. 143 9. Chapter 9 Environmental pollution, epigenetics, and cancer - p. 175 10. Chapter 10 Synthetic biology and cell engineering—deriving new insights into cancer epigenetics - p. 195 11. Chapter 11 Epigenetic targeted therapies in hematological malignancies - p. 213 12. Chapter 12 Epigenetic therapy in lung cancer - p. 237 13. Chapter 13 Breast cancer epigenetics - p. 275 14. Chapter 14 Therapeutic applications of the prostate cancer epigenome - p. 301 15. Chapter 15 Neuroblastoma - p. 339 16. Chapter 16 Epigenetic therapies—update on lysine methyltransferase/PRC complex inhibitors - p. 373 17. Chapter 17 Inhibitors of Jumonji-C domain-containing histone demethylases - p. 407 18. Chapter 18 Emerging epigenetic therapies—lysine acetyltransferase inhibitors - p. 459 19. Chapter 19 Epigenetic therapies: histone deacetylases - p. 507 20. Chapter 20 Epigenetic intratumoral heterogeneity - p. 541 21. Chapter 21 Challenges for single-cell epigenetic analysis - p. 553 22. Chapter 22 Epigenetics of cisplatin resistance - p. 577 23. Chapter 23 Emerging epigenetic therapies: protein arginine methyltransferase inhibitors - p. 613 24. Chapter 24 Personalized epigenetic therapy—chemosensitivity testing - p. 637 25. Chapter 25 Epigenetic profiling in cancer: triage, prognosis, and precision oncology - p. 651 26. Chapter 26 Epigenetic priming—fact or falacy? - p. 675 27. Chapter 27 CRISPR, epigenetics, and cancer - p. 687 28. Index - p. 709
Epigenetic Cancer Therapy, Second Edition provides a comprehensive discussion of healthy and aberrant epigenetic biology, along with new discoveries to improve our understanding of cancer epigenetics and therapeutics. The book encompasses large-scale intergovernmental initiatives, as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Since the publication of the first edition of this book, the field of epigenetics has undergone significant change. New epigenetic therapies have been designed and approved for clinical use.
Our knowledge of the plasticity of the epigenome in cancer and disease has expanded dramatically, with increasing evidence linking pollution to epigenetic changes in cancer development. This second edition has been fully updated to address these changes, along with promising therapeutic programs such as CRISPR/Cas9 mediated approaches, CAR-T based therapies, epigenetic priming, histone modifications, and similar, transformative advances across synthetic biology and cellular engineering.
1. Chapter 1 Introduction - p. 1 2. Chapter 2 Methylation and hydroxymethylation in cancer - p. 11 3. Chapter 3 Writers, erasers, and readers of DNA and histone methylation marks - p. 39 4. Chapter 4 Oncohistones - p. 65 5. Chapter 5 microRNA, epi-microRNA, and cancer - p. 85 6. Chapter 6 Long noncoding RNA in human cancers: to be or not to be, that is the question - p. 109 7. Chapter 7 The emerging roles of epitranscriptomic marks in cancer - p. 129 8. Chapter 8 Epigenomic profiling at genome scale: from assays and analysis to clinical insights - p. 143 9. Chapter 9 Environmental pollution, epigenetics, and cancer - p. 175 10. Chapter 10 Synthetic biology and cell engineering—deriving new insights into cancer epigenetics - p. 195 11. Chapter 11 Epigenetic targeted therapies in hematological malignancies - p. 213 12. Chapter 12 Epigenetic therapy in lung cancer - p. 237 13. Chapter 13 Breast cancer epigenetics - p. 275 14. Chapter 14 Therapeutic applications of the prostate cancer epigenome - p. 301 15. Chapter 15 Neuroblastoma - p. 339 16. Chapter 16 Epigenetic therapies—update on lysine methyltransferase/PRC complex inhibitors - p. 373 17. Chapter 17 Inhibitors of Jumonji-C domain-containing histone demethylases - p. 407 18. Chapter 18 Emerging epigenetic therapies—lysine acetyltransferase inhibitors - p. 459 19. Chapter 19 Epigenetic therapies: histone deacetylases - p. 507 20. Chapter 20 Epigenetic intratumoral heterogeneity - p. 541 21. Chapter 21 Challenges for single-cell epigenetic analysis - p. 553 22. Chapter 22 Epigenetics of cisplatin resistance - p. 577 23. Chapter 23 Emerging epigenetic therapies: protein arginine methyltransferase inhibitors - p. 613 24. Chapter 24 Personalized epigenetic therapy—chemosensitivity testing - p. 637 25. Chapter 25 Epigenetic profiling in cancer: triage, prognosis, and precision oncology - p. 651 26. Chapter 26 Epigenetic priming—fact or falacy? - p. 675 27. Chapter 27 CRISPR, epigenetics, and cancer - p. 687 28. Index - p. 709
